Replies to post #206039 on Cytodyn Inc (CYDY)

[misiu143]

62 critical patients with 82% mortality benefit ABOVE all those toxic , mostly worthless SOC drugs at 14 days , and not to be approve during pandemic need to be investigated...

Lets remember ibalizumab for combo HIV was approved with a phase 3 study of 40 patients..

So all this is just an excuse ..

Yep , vaccination must be mandate...

All IMO.

[HyGro]

It wasn't a random selection -- it didn't have a matched panel, it wasn't a quota sample that would be required to be a viable subsample. It was a post-hoc, data dredged sample.

The critical patient sample was not statistically significant -- NP used inappropriate statistical methods to claim it was. The FDA Statement reprimanded him for misrepresenting and manipulating the CoV data.

Trials for an indication are ONLY useable for that indication and aren't used for other indications other than possibly for safety to help start Phase 2 for other indications.

Brazil trial is dragging significantly and the company is running out of money and may not be able to complete. The U.S. trial is not likely to happen, again no cash to finance. It is looking less likely that the company will be able to complete a trial that will meet U.S. FDA requirements.

[3X Charm]

No different than CYDY having a lead at half time, only to get blown out in the 4th quarter. The only thing that matters Is the finish. Did the trial meet endpoints for any set metrics?

NOPE.